Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings suggest that at least one of these drugs may be an effective treatment for individuals in the early course of the illness.